Filing Summary
Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Form 8-K on October 7, 2026, reporting an offer concerning warrants issued in its September 18, 2025 underwritten public offering. This is an event filing, not a periodic financial-results report.
Offer Terms and Key Metrics
- Jasper is offering warrant holders $0.324 in cash, without interest, for each outstanding warrant tendered.
- Each warrant entitles its holder to purchase one share of common stock at an exercise price of $2.92, subject to adjustment.
- As of October 6, 2026, 12,345,707 warrants were outstanding. If all were tendered and accepted, the stated cash consideration would total approximately $4.0 million, before expenses.
- The offer is scheduled to remain open until one minute after 11:59 p.m. Eastern Time on November 6, 2026, unless extended.
Changes, Outlook, and Risks
The filing does not report revenue, profit, cash flow, margins, debt, liquidity, or comparative-period financial results. It provides no business guidance or financial outlook. The offer is governed by the October 7, 2026 Offer to Purchase and related materials; the 8-K does not provide their full terms or conditions.
Important Facts to Verify
- Review the Offer to Purchase and related materials for eligibility, conditions, tender procedures, and any withdrawal rights.
- Confirm whether Jasper extends the offer or changes its terms before the stated deadline.
- Verify the final number of warrants tendered and accepted, and the resulting cash payment and impact on potential share dilution.